美托洛尔治疗风湿性心脏病慢性心力衰竭的临床疗效

Clinical effect analysis of metoprolol in treating patients with rheumatic heart disease and chronic heart failure

目的探讨美托洛尔治疗风湿性心脏病慢性心力衰竭的临床疗效。方法将2019年1月至2020年1月在我院心内科治疗的86例风湿性心脏病慢性心力衰竭患者随机分为两组,对照组使用常规抗心衰药物治疗,在此基础上,观察组使用美托洛尔治疗,对比组间的临床疗效、心功能指标变化、NT-proBNP水平变化、炎症因子水平变化。结果观察组治疗总有效率为93.02%,明显高于对照组的72.09%(P<0.05);观察组治疗后LVEF为(44.98±5.09)%,明显高于对照组的(39.10±6.28)%,LVEDD为(52.89±8.04)mm、LVESD为(41.32±5.72)mm,明显低于对照组的(57.01±8.63)mm、(45.03±6.27)mm(P<0.05);观察组治疗1周、2周、3周、4周的NT-proBNP水平分别为(2373.80±795.47)pg/mL、(1587.23±413.35)pg/mL、(1032.79±311.64)pg/mL、(602.28±170.13)pg/mL,明显低于对照组的(3125.42±1006.17)pg/mL、(2865.92±698.74)pg/mL、(2612.58±649.83)pg/mL、(2379.95±564.32)pg/mL(P<0.05)。结论美托洛尔治疗风湿性心脏病慢性心力衰竭的临床疗效显著,能有效抑制炎症反应、心室重构,减轻心肌损伤,保护心功能,具有积极的临床意义。

Objective To investigate the clinical effect analysis of metoprolol in treating patients with rheumatic heart disease and chronic heart failure.Methods A total of 86 patients with rheumatic heart disease and chronic heart failure treated in the department of cardiology of our hospital from January 2019 to January 2020 were randomly divided into two groups.The control group was treated with routine anti-heart failure drugs,while the observation group was additionally treated with metoprolol on the basis of the control group.The clinical efficacy,cardiac function index change,NT-proBNP level change,inflammatory factor level change were compared between groups.Results The total effective rate of treatment was 93.02%in the observation group,which was significantly higher than 72.09%in the control group(P<0.05).After treatment,LVEF(44.98±5.09)%in the observation group was significantly higher than that in the control group(39.10±6.28)%,LVEDD(52.89±8.04)mm and LVESD(41.32±5.72)mm were significantly lower than those in the control group(57.01±8.63)mm and(45.03±6.27)mm(P<0.05).The NT-proBNP levels in the observation group at 1,2,3 and 4 weeks of treatment were(2373.80±795.47)pg/mL,(1587.23±413.35)pg/mL,(1032.79±311.64)pg/mL,(602.28±170.13)pg/mL,respectively,which were significantly lower than those in the control group at 1,2,3 and 4 weeks of treatment([3125.42±1006.17]pg/mL,[2865.92±698.74]pg/mL,[2612.58±649.83]pg/mL,and[2379.95±564.32]pg/mL)(P<0.05).Conclusion Metoprolol has significant clinical effect in treating patients with rheumatic heart disease and chronic heart failure.It can effectively inhibit inflammatory response and ventricular remodeling,reduce myocardial damage,and protect cardiac function,which has positive clinical significance.